

# MedStar Health, Inc.

## POLICY AND PROCEDURE MANUAL

Policy Number: MP.083.MH  
Last Review Date: 11/08/2018  
Effective Date: 01/01/2019

### MP.083.MH – Skin Substitutes- Human Skin Equivalents

This policy applies to the following lines of business:

- ✓ MedStar Employee (Select)
- ✓ MedStar CareFirst PPO

MedStar Health considers **Skin Substitutes- Human Skin Equivalents (HSE)** medically necessary for the following indications:

**AlloDerm** is covered for medically necessary breast reconstruction. *All other applications are considered experimental and investigational.*

**APLIGRAF® (formerly marketed as Graftskin)** is indicated for the treatment of venous insufficiency ulcers in conjunction with the recommended post-application compression therapy when all of the following are met:

1. The treatment is specific to non-infected partial or full-thickness skin ulcers, at least 1.0 cm<sup>2</sup> in size, due to clinically documented venous insufficiency (venous insufficiency should be objectively documented either by history of previous deep venous thrombosis in the index leg, or objective documentation of valvular reflux by duplex ultrasound, venography, or air/photo plethysmography); And
2. The ulcer(s) is of at least four weeks in duration; And
3. The medical record supports that the ulcer(s) has been treated by the provider applying the human skin equivalents (HSE) with conventional non-surgical therapy for a minimum of four weeks and has failed to decrease in size, and the ulcer(s) has not shown any indication (e.g., epithelial in growth and progression towards closure) that improvement is likely;  
Or  
The medical record supports that the ulcer is so clinically severe that it requires immediate, aggressive therapy; And
4. Adequate circulation/oxygenation supported by documented physical examination and an Ankle-Brachial Index (ABI) of no less than 0.65; And
5. The member is competent and/or has the support services required to participate in follow-up care associated with the treatment of the wound following the application of Apligraf®;

OR

## MP.083.MH – Skin Substitutes- Human Skin Equivalents

Policy Number: MP.083.MH

Last Review Date: 11/08/2018

Effective Date: 01/01/2019

**APLIGRAF® (Graftskin)** is indicated for the treatment of diabetic foot ulcers in conjunction with the recommended post-application compression therapy when all of the following are met:

1. The treatment is specific to non-infected full thickness foot ulcers, at least 1.0 cm<sup>2</sup> in size, due to clinically documented diabetic neuropathy (type 1 or type 2 diabetes should be objectively documented as well as the current medical management for the diabetes, including medical management of neuropathy); And
2. The ulcer is of at least three (3) weeks in duration; And
3. The ulcer is located on the surface of the foot and is free of infection, tunnels, and tracts. The ulcer must be free of cellulitis, eschar, or obvious necrotic material as this will interfere with the device adherence and wound healing; And
4. The ulcer extends through the dermis but it does not involve the tendon, muscle, capsule or have bone exposure; And
5. The medical record supports that the ulcer(s) has been treated by the provider applying the HSE with conventional non-surgical therapy for a minimum of three (3) weeks and has failed to decrease in size; And
6. The ulcer(s) has not shown any indication (e.g., epithelial in-growth and progression towards closure) that improvement is likely;  
Or  
The medical record supports that the ulcer is so clinically severe that it requires immediate, aggressive therapy; And
7. The extremity is free of active Charcot's arthropathy; And
8. The member must have adequate arterial blood supply to support tissue growth; And
9. The member is competent and/or has the support system required to participate in the follow-up care associated with treatment of the wound with Apligraf®.

**DERMAGRAFT®** is indicated for the treatment of diabetic foot ulcers when all of the following are met and documented:

1. The treatment is specific to non-infected full thickness diabetic foot ulcers, is at least 1.0 cm<sup>2</sup> in size, (type 1 or type 2 diabetes should be objectively documented as well as the current medical management for the diabetes); And
2. The ulcer is of at least three weeks in duration; And
3. The ulcer is located on the surface of the foot and is free of infection, tunnels, and tracts, cellulitis, eschar, or obvious necrotic material as this will interfere with the device adherence and wound healing; And
4. The ulcer extends through the dermis but it does not involve the tendon, muscle, joint capsule or have bone exposure; And

## MP.083.MH – Skin Substitutes- Human Skin Equivalents

Policy Number: MP.083.MH

Last Review Date: 11/08/2018

Effective Date: 01/01/2019

5. The medical record supports that the ulcer(s) has been treated by the provider applying the HSE with conventional non-surgical therapy for a minimum of three weeks and has failed to decrease in size; And
6. The ulcer(s) has not shown any indication (e.g., epithelial in-growth and progression towards closure) that improvement is likely;  
OR  
The medical record supports that the ulcer is so clinically severe that it requires immediate, aggressive therapy; And
7. The extremity must be free of active Charcot's arthropathy; And
8. The member must have adequate arterial blood supply to support tissue growth; And
9. The member is competent and/or has the support system required to participate in follow-up care associated with treatment of the wound with Dermagraft®.

**EpiFix® Amniotic Membrane** is indicated for the treatment of diabetic foot ulcers and venous stasis ulcers when all of the following are met and documented:

1. Diabetic foot ulcer
  - Partial or full-thickness, diabetic foot ulcer
  - Type 1 or type 2 diabetes mellitus
  - Failed standard wound therapy
2. Venous stasis ulcer
  - Partial or full-thickness venous stasis ulcer
  - Failed standard wound therapy

**EpiCord** is a non-viable cellular human umbilical cord allograft intended to provide an extracellular matrix as a scaffold in the form of fibrillar collagens, fibronectin, laminins, and proteoglycans. Compared to EpiFix, EpiCord has a thicker and stiffer composition allowing physicians to apply it to deep tunneling wounds.

EpiCord is considered medically necessary when the member has:

- Diabetic foot ulcers that have not healed with standard therapy attempted for at least 1 month but not greater than 52 weeks.

**Graftjacket® Regenerative Tissue Matrix** (non injectable) is covered for open wound of wrist, hand or fingers with tendon involvement. It is considered experimental and investigational for all other indications, and will therefore deny. It is considered experimental and investigational for all other indications.

**INTEGRA Dermal Regeneration Template and Flowable Wound Matrix** is indicated for the treatment of:

1. Severe (2<sup>nd</sup> or 3<sup>rd</sup> degree) burns  
Or  
Burn scars/contracture reconstructive surgery

## MP.083.MH – Skin Substitutes- Human Skin Equivalents

Policy Number: MP.083.MH

Last Review Date: 11/08/2018

Effective Date: 01/01/2019

Or

Significant open wounds, such as severe necrotizing fasciitis

And

2. When there is a limited amount of member's skin for autografts

Or

The member is too ill to have more wound graft sites created.

**INTEGRA Meshed Bilayer Wound Matrix** is indicated for the treatment of:

1. Diabetic ulcers that are greater than six weeks in duration, not involving muscle, tendon, ligament or severe burns where allograft is not possible, when used in conjunction with standard diabetic ulcer care, OR;
2. Severe burns where there is a limited amount of member's skin for autografts, OR;
3. Severe burns where member is too ill to have wound sites created for autografts.

**OASIS WOUND MATRIX® and OASIS Tri-Layer Wound Matrix:**

1. The product is being used for the management of wounds including:
  - Treatment of neuropathic diabetic foot ulcers that have failed conservative measures of at least four weeks duration.  
Or
  - When used in association with a medically necessary breast reconstruction surgery  
Or
  - Treatment of partial and full-thickness skin venous insufficiency ulcers present for a minimum of four weeks duration and have failed conventional treatment for at least two weeks.  
Or
  - Skin substitute used in conjunction with standard wound care regiment.  
And
2. The medical record clearly documents that the product is being used in an office or clinic based comprehensive, organized wound management program

**TheraSkin** is indicated when used for any of the following:

1. In conjunction with standard therapeutic compression for the treatment of chronic, non-infected, partial or full-thickness skin ulcers due to venous insufficiency of greater than one month in duration and which have not adequately responded to a four week period of conventional ulcer therapy (such as standard dressing changes, and standard therapeutic compression)  
Or
2. In conjunction with standard diabetic foot ulcer care for the treatment of full-thickness neuropathic diabetic foot ulcers of greater than one month duration which

## MP.083.MH – Skin Substitutes- Human Skin Equivalents

Policy Number: MP.083.MH  
Last Review Date: 11/08/2018  
Effective Date: 01/01/2019

have not adequately responded following at least a four week period of conventional ulcer therapy (such as surgical debridement, complete off-loading and standard dressing changes) and which can extend through the dermis, including tendon, muscle, joint capsule or bone exposure

Or

3. Large surgical wounds

Or

4. Pressure ulcers

### Limitations

#### Apligraf®

1. A single application of Apligraf® may be all that is required to affect the wound healing in those wounds that are likely to improve by this therapy.
  - The use of additional applications if less than 50% “take” is observed, is limited to a total of four additional applications for the same ulcer.
  - Additional applications beyond this for one year are considered not medically necessary.
  - Apligraf® is not covered for use with acute surgical wounds, pressure sores and burns.

2. Retreatment:

- Within one year following the last successful Apligraf® application is considered not medically necessary.
- Of an ulcer following the unsuccessful treatment where it consisted of two failed Apligraf® applications is considered not medically necessary.

NOTE: Debridement of the ulcer is not payable during active treatment with Apligraf®, except for debridement prior to re-applications, or prior to retreatment.

3. Contraindications:

- Clinically infected wounds (i.e. increased exudate, odor, redness, swelling, heat, pain, tenderness to the touch, purulent drainage);
- Known allergies to bovine collagen; and
- A known hypersensitivity to the components of the agarose shipping medium

#### Dermagraft®

1. A single application of Dermagraft® may be all that is required to affect the wound healing in those wounds that are likely to improve by this therapy.
  - The use of additional applications if less than 50% “take” is observed, is limited to a total of seven additional applications for the same ulcer.

## MP.083.MH – Skin Substitutes- Human Skin Equivalents

Policy Number: MP.083.MH

Last Review Date: 11/08/2018

Effective Date: 01/01/2019

- Additional applications beyond this for one year are considered not medically necessary.
  - Dermagraft® is not covered for use with acute surgical wounds, pressure sores and burns.
2. Retreatment:
- Within one year following the last successful Dermagraft® application is considered not medically necessary.
  - Of an ulcer following the unsuccessful treatment where it consisted of two failed Dermagraft® applications is considered not medically necessary.
- NOTE: Debridement of the ulcer is not payable during active treatment with Dermagraft®, except for debridement prior to re-applications, or prior to retreatment.
3. Contraindications:
- Clinically infected ulcers (i.e. increased exudate, odor, redness, swelling, heat, pain, tenderness to the touch, purulent discharge) or ulcers with sinus tracts;
  - Known hypersensitivity to bovine products, as it may contain trace amounts of bovine proteins from the manufacturing medium and storage solution.

### Integra

1. Use of Integra for any other indications than those listed in this policy will result in a claims denial.
2. Contraindications:
  - Clinically infected ulcers (i.e. increased exudate, odor, redness, swelling, heat, pain, tenderness to the touch, purulent discharge) or ulcers with sinus tracts;
  - Known hypersensitivity or allergy to bovine products

### Oasis® Wound Matrix

1. A non-adherent, secondary dressing should be used over the Oasis® Wound Matrix to maintain a moist wound environment.
2. Oasis Tri-layer Wound Matrix is not indicated for use in association with a medically necessary breast reconstruction surgery.

### TheraSkin

The use of TheraSkin on an ulcer with any of the following conditions is not considered medically necessary and will result in a claims denial:

- Cellulitis;
- Osteomyelitis;
- Necrotic ulcer;
- Draining wound;
- Clinically significant wound healing impairment due to uncontrolled diabetes.

### Human Skin Equivalents/Skin Substitutes

## MP.083.MH – Skin Substitutes- Human Skin Equivalents

Policy Number: MP.083.MH

Last Review Date: 11/08/2018

Effective Date: 01/01/2019

The application of HSE is limited to clinicians and physicians who are highly skilled in wound care management and have experience in the use of HSE for the treatment of wounds.

1. HSE should be applied to a clean ulcer that has undergone one detailed debridement prior to each application.
2. The member should be under the care of a physician for the treatment and monitoring of their systemic disease processes.
3. Prior to HSE application:
  - The medical record documentation should contain evidence that the conservative measures have failed, or support that the ulcer is so clinically severe that it requires immediate, aggressive therapy.
  - The medical record should indicate failure of the ulcer to decrease in size and depth, or that there has been no change in baseline size or depth with no signs of improvement, or no indication that improvement is likely.
4. Medical record documentation should contain the frequency of the HSE application for both venous insufficiency ulcers and neuropathic diabetic foot ulcers and be consistent with each member's specific history and response to the device application.
5. Contraindications:
  - Clinically infected wounds (i.e., increased exudate, odor, redness, swelling, heat, pain, tenderness to the touch, purulent discharge)
  - Known allergies to bovine collagen - for bovine derived products
  - Known hypersensitivity to the components of the agarose (gel-like substance derived from seaweed) shipping medium.
6. Not medically necessary applications of Apligraf® and Dermagraft ®
  - Surgical wounds,
  - Pressure sores, and
  - Burns
7. **Experimental and Investigational:**
  - AlloSkin skin substitute
  - Amnioarmor
  - Amnioexcel or Biodexcel
  - AmnioFix
  - Amniomatrix or Biodmatrix
  - Artacent
  - Arthroflex
  - Artiss (Human plasma fibrin sealant, vapor-heated, solvent-detergent)
  - Biodfence
  - Cellesta
  - Cellesta Flowable Amnion
  - Coll-E-Derm

## MP.083.MH – Skin Substitutes- Human Skin Equivalents

Policy Number: MP.083.MH

Last Review Date: 11/08/2018

Effective Date: 01/01/2019

- Dermacell
- Derma-Gide
- Endoform Dermal Template
- Excellagen
- FlexHD (AKA: AlloPatch)
- Genesis Amniotic Membrane
- Graftjacket® Regenerative Tissue Matrix- (*non injectable*) \*
- Graftjacket X-Press® Flowable Soft Tissue Scaffold (*injectable*)
- Keroxx
- Matrion
- Memoderm
- NeoX
- NeuroMend Collagen Nerve Wrap (Collagen matrix nerve wrap )
- Permacol Porcine implant
- Novachor
- Primatrix
- Puraply
- Repriza
- Restorigin
- Skinte
- Strattice
- Tensix
- Oasis Burn Matrix
- Oasis Ultra Tri-Layer Matrix
- Surgigraft
- SurgiMend Collagen Matrix (Dermal substitute, native, non-denatured collagen, neonatal bovine origin)
- Talymed
- Unite Biomatrix
- XCM Biologic Tissue Matrix

### Background

In the United States, the total prevalence of chronic wounds related to venous ulcers, diabetic foot ulcers, and pressure sores, has been estimated to range from 3 to 6 million. These wounds are categorized as chronic as they have occurred in duration for a minimum of four weeks. Skin substitutes, also referred to as human skin equivalents (HSE), are tissue-engineered products using human cells, animal cells, or both, in a scaffold of natural or synthetic extracellular matrices. The extracellular matrices provide mechanical stability and a 3-dimensional framework for eventual tissue infiltration and development, and can also promote wound healing by stimulating the host to produce a variety of cytokines.



## MP.083.MH – Skin Substitutes- Human Skin Equivalents

Policy Number: MP.083.MH  
 Last Review Date: 11/08/2018  
 Effective Date: 01/01/2019

### Codes:

<b>CPT Codes / HCPCS Codes / ICD-10 Codes</b>	
Code	Description
<b>CPT Codes</b>	
15271	Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area
15272	Application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof
15273	Application of skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children
15274	Application of skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof
15275	Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area
15276	Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof
15277	Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children
15278	Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof
15777	Implantation of biologic implant (eg, acellular dermal matrix) for soft tissue reinforcement (eg, breast, trunk)
<b>HCPCS codes covered if selection criteria are met (If Appropriate):</b>	
Q4101	Apligraf, per square centimeter

## MP.083.MH – Skin Substitutes- Human Skin Equivalents

Policy Number: MP.083.MH  
 Last Review Date: 11/08/2018  
 Effective Date: 01/01/2019

Q4102	Oasis Wound Matrix, per square centimeter
Q4104	Skin Substitute, Integra Bilayer Matrix Wound Dressing (BMWD), per sq cm
Q4105	Skin Substitute, Integra Dermal Regeneration Template (DRT), per sq cm
Q4108	Integra Matrix, per sq cm
Q4114	Integra™ Flowable Wound Matrix
Q4106	Dermagraft, per square centimeter
Q4121	TheraSkin, per square centimeter
<b>Alloderm code covered when billed with any of the following breast reconstruction diagnoses:</b>	
Q4116	Alloderm, per sq cm
<b>HCPCS Codes requiring Prior Authorization</b>	
Q4186	Epifix, per sq cm
Q4187	Epicord, per sq cm
<b>ICD-10 codes</b>	
C44.500	Unspecified malignant neoplasm of anal skin
C44.501	Unspecified malignant neoplasm of skin of breast
C44.509	Unspecified malignant neoplasm of skin of other part of trunk
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast
C50.929	Malignant neoplasm of unspecified site of unspecified male breast
C50.119	Malignant neoplasm of central portion of unspecified female breast
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast
C50.619	Malignant neoplasm of axillary tail of unspecified female breast
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast
C50.919	Malignant neoplasm of unspecified site of unspecified female breast
C79.2	Secondary malignant neoplasm of skin
C79.81	Secondary malignant neoplasm of breast
D05.90	Unspecified type of carcinoma in situ of unspecified breast

## MP.083.MH – Skin Substitutes- Human Skin Equivalents

Policy Number: MP.083.MH  
 Last Review Date: 11/08/2018  
 Effective Date: 01/01/2019

D07.39	Carcinoma in situ of other female genital organs
D48.60	Neoplasm of uncertain behavior of unspecified breast
D49.3	Neoplasm of unspecified behavior of breast
Z85.3	Personal history of malignant neoplasm of breast
Z90.10	Acquired absence of unspecified breast and nipple
<b>Graftjacket code covered when billed with any of the following diagnoses:</b>	
Q4107	Graftjacket skin substitute ( <i>non injectable</i> ), per sq cm
<b>ICD-10 codes</b>	
S61.109A	Unspecified open wound of unspecified thumb with damage to nail, initial encounter
S61.209A	Unspecified open wound of unspecified finger without damage to nail, initial encounter
S61.409A	Unspecified open wound of unspecified hand, initial encounter
S61.509A	Unspecified open wound of unspecified wrist, initial encounter
S66.021A	Laceration of long flexor muscle, fascia and tendon of right thumb at wrist and hand level, initial encounter
S66.022A	Laceration of long flexor muscle, fascia and tendon of left thumb at wrist and hand level, initial encounter
S66.029A	Laceration of long flexor muscle, fascia and tendon of unspecified thumb at wrist and hand level, initial encounter
S66.120A	Laceration of flexor muscle, fascia and tendon of right index finger at wrist and hand level, initial encounter
S66.121A	Laceration of flexor muscle, fascia and tendon of right index finger at wrist and hand level, initial encounter
S66.122A	Laceration of flexor muscle, fascia and tendon of right middle finger at wrist and hand level, initial encounter
S66.123A	Laceration of flexor muscle, fascia and tendon of left middle finger at wrist and hand level, initial encounter
S66.124A	Laceration of flexor muscle, fascia and tendon of right ring finger at wrist and hand level, initial encounter
S66.125A	Laceration of flexor muscle, fascia and tendon of left ring finger at wrist and hand level, initial encounter
S66.126A	Laceration of flexor muscle, fascia and tendon of right little finger at wrist and hand level, initial encounter

## MP.083.MH – Skin Substitutes- Human Skin Equivalents

Policy Number: MP.083.MH  
Last Review Date: 11/08/2018  
Effective Date: 01/01/2019

S66.127A	Laceration of flexor muscle, fascia and tendon of left little finger at wrist and hand level, initial encounter
S66.128A	Laceration of flexor muscle, fascia and tendon of other finger at wrist and hand level, initial encounter
S66.129A	Laceration of flexor muscle, fascia and tendon of unspecified finger at wrist and hand level, initial encounter
S66.221A	Laceration of extensor muscle, fascia and tendon of right thumb at wrist and hand level, initial encounter
S66.229A	Laceration of extensor muscle, fascia and tendon of unspecified thumb at wrist and hand level, initial encounter
S66.320A	Laceration of extensor muscle, fascia and tendon of right index finger at wrist and hand level, initial encounter
S66.321A	Laceration of extensor muscle, fascia and tendon of left index finger at wrist and hand level, initial encounter
S66.322A	Laceration of extensor muscle, fascia and tendon of right middle finger at wrist and hand level, initial encounter
S66.323A	Laceration of extensor muscle, fascia and tendon of left middle finger at wrist and hand level, initial encounter
S66.324A	Laceration of extensor muscle, fascia and tendon of right ring finger at wrist and hand level, initial encounter
S66.325A	Laceration of extensor muscle, fascia and tendon of left ring finger at wrist and hand level, initial encounter
S66.326A	Laceration of extensor muscle, fascia and tendon of right little finger at wrist and hand level, initial encounter
S66.327A	Laceration of extensor muscle, fascia and tendon of left little finger at wrist and hand level, initial encounter
S66.328A	Laceration of extensor muscle, fascia and tendon of other finger at wrist and hand level, initial encounter
S66.329A	Laceration of extensor muscle, fascia and tendon of unspecified finger at wrist and hand level, initial encounter
S66.421A	Laceration of intrinsic muscle, fascia and tendon of right thumb at wrist and hand level, initial encounter
S66.422A	Laceration of intrinsic muscle, fascia and tendon of left thumb at wrist and hand level, initial encounter
S66.429A	Laceration of intrinsic muscle, fascia and tendon of unspecified thumb at wrist

## MP.083.MH – Skin Substitutes- Human Skin Equivalents

Policy Number: MP.083.MH  
 Last Review Date: 11/08/2018  
 Effective Date: 01/01/2019

	and hand level, initial encounter
S66.520A	Laceration of intrinsic muscle, fascia and tendon of right index finger at wrist and hand level, initial encounter
S66.521A	Laceration of intrinsic muscle, fascia and tendon of left index finger at wrist and hand level, initial encounter
S66.522A	Laceration of intrinsic muscle, fascia and tendon of right middle finger at wrist and hand level, initial encounter
S66.523A	Laceration of intrinsic muscle, fascia and tendon of left middle finger at wrist and hand level, initial encounter
S66.524A	Laceration of intrinsic muscle, fascia and tendon of right ring finger at wrist and hand level, initial encounter
S66.525A	Laceration of intrinsic muscle, fascia and tendon of left ring finger at wrist and hand level, initial encounter
S66.526A	Laceration of intrinsic muscle, fascia and tendon of right little finger at wrist and hand level, initial encounter
S66.527A	Laceration of intrinsic muscle, fascia and tendon of left little finger at wrist and hand level, initial encounter
S66.528A	Laceration of intrinsic muscle, fascia and tendon of other finger at wrist and hand level, initial encounter
S66.529A	Laceration of intrinsic muscle, fascia and tendon of unspecified finger at wrist and hand level, initial encounter
S66.821A	Laceration of other specified muscles, fascia and tendons at wrist and hand level, right hand, initial encounter
S66.822A	Laceration of other specified muscles, fascia and tendons at wrist and hand level, left hand, initial encounter
S66.829A	Laceration of other specified muscles, fascia and tendons at wrist and hand level, unspecified hand, initial encounter
S66.921A	Laceration of unspecified muscle, fascia and tendon at wrist and hand level, right hand, initial encounter
S66.922A	Laceration of unspecified muscle, fascia and tendon at wrist and hand level, left hand, initial encounter
S66.929A	Laceration of unspecified muscle, fascia and tendon at wrist and hand level, unspecified hand, initial encounter

### Variations – Medicare

## MP.083.MH – Skin Substitutes- Human Skin Equivalents

Policy Number: MP.083.MH

Last Review Date: 11/08/2018

Effective Date: 01/01/2019

The following skin substitutes are indicated for Medicare products only and will be denied as Experimental and Investigational for all other [client] products (this is not an all-inclusive list):

- Primatrix
- GammaGraft
- AlloSkin
- Hyalomatrix
- Matristem micromatrix
- Matristem wound matrix
- Matristem burn matrix
- Dermacell
- Memoderm/derma/tranz/integup
- Talymed
- Unite biomatrix
- Grafix core
- Grafix prime
- hMatrix
- Mediskin
- EZderm
- Amnioexcel or biodexcel, 1cm
- Biodfence 1cm
- Alloskin ac, 1 cm
- Neox 1k, 1cm
- AmnioBand, guardian 1 sq cm
- Dermapure 1 square cm
- Dermavest 1 square cm
- Biovance 1 square cm
- Neox 100 1 square cm
- Revitalon 1 square cm
- MariGen 1 square cm
- Affinity1 square cm
- NuShield 1 square cm

### References

1. American Burn Association White Paper: Surgical Management of the Burn Wound and the Use of Skin Substitutes, 2009  
<http://www.ucdenver.edu/academics/colleges/medicalschoo/departments/surgery/divisions/GITES/burn/Documents/American%20Burn%20Association%20White%20Paper.pdf>

## MP.083.MH – Skin Substitutes- Human Skin Equivalents

Policy Number: MP.083.MH

Last Review Date: 11/08/2018

Effective Date: 01/01/2019

2. Centers for Medicare and Medicaid Services (CMS). Local Coverage Determination (LCD) No L34938. Removal of Benign or Premalignant Skin Lesions. Revision Effective Date: 10/01/2018. <https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=34938&ver=52&Date=&DocID=L34938&bc=iAAAABAAAAAA&AA&>
3. Cuadra A, Correa G, Roa R, et al. Functional results of burned hands treated with Integra®. *J Plast Reconstr Aesthet Surg*. 2012 Feb; 65(2):228-234. <https://www.ncbi.nlm.nih.gov/pubmed/22041337>
4. DiDomenico L, Emch KJ, Landsman A, et al. A prospective comparison of diabetic foot ulcers treated with either a cryopreserved skin allograft or a bioengineered skin substitute. *Wounds*. 2011;23(7):184–189 <https://www.woundsresearch.com/article/prospective-comparison-diabetic-foot-ulcers-treated-either-cryopreserved-skin-allograft-or-0>
5. Felder III JM, Goyal SS, Attinger CE. A systematic review of skin substitutes for foot ulcers. *Plast Reconstr Surg* 2012 Jul;130(1):145-164. doi: 10.1097/PRS.0b013e318254b1ea. <http://www.ncbi.nlm.nih.gov/pubmed/22743881>
6. Greaves NS, Iqbal SA, Baguneid M, et al. The role of skin substitutes in the management of chronic cutaneous wounds. *Wound Repair Regen*. 2013 Mar-Apr;21(2):194-210. doi: 10.1111/wrr.12029. Epub 2013 Feb 25. <http://www.ncbi.nlm.nih.gov/pubmed/23437811>
7. Greer N, Foman N, Dorrian J, et al. Advanced Wound Care Therapies for Non-Healing Diabetic, Venous, and Arterial Ulcers: A Systematic Review [Internet]. VA Evidence-based Synthesis Program Reports. 2012 Nov. Available at: <http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0054957/pdf/TOC.pdf>
8. Halim A, Khoo T, Yusoof S. Biologic and synthetic skin substitutes: An overview. *Indian J Plast Surg*. September 2010. 43(Suppl): S23-S28). <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038402/?report=printable>
9. Han G. State-of-the-art wound healing: skin substitutes for chronic wounds. *Cutis*. 2014 Jan;93(1):E13-6. <https://www.ncbi.nlm.nih.gov/pubmed/24505591>  
Hayes Medical Technology Directory. Biological Tissue-Engineered Skin Substitutes for Wound Healing. Annual Review February 11, 2014. Archived February 28, 2015.
10. Hayes Medical Technology Directory. Biosynthetic Tissue-Engineered Skin Substitutes for Wound Healing. Annual Review February 14, 2014. Archived February 14, 2015.
11. Hayes Health Technology Brief. Oasis Wound Matrix (Cook Biotech Inc.) for Lower Extremity Ulcers. Annual Review December 12, 2014. Archived January 31, 2016.

## MP.083.MH – Skin Substitutes- Human Skin Equivalents

Policy Number: MP.083.MH

Last Review Date: 11/08/2018

Effective Date: 01/01/2019

12. Hayes Health Technology Brief. EpiFix (MiMedx Group) for Treatment of Nonhealing Wounds. Published August 20, 2015. Annual Review Jul 13, 2017. Archived Nov 09, 2017.
13. Skin Substitutes for Nonhealing Wounds – Product Comparison. Clinical Research Response. August 27, 2018.
14. Landsman A, Cook J, Cook E, et al: A retrospective clinical study of 188 consecutive patients to examine the effectiveness of a biologically active cryopreserved human skin allograft (TheraSkin®) on the treatment of diabetic foot ulcers and venous leg ulcers. Foot Ankle Spec. 2011 Feb;4(1):29-41  
<http://www.ncbi.nlm.nih.gov/pubmed/21135263>
15. Langer A, Rogowski W. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Serv Res. 2009 Jul 10;9:115. doi: 10.1186/1472-6963-9-115.  
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716319/pdf/1472-6963-9-115.pdf>
16. Mazzone L, Schiesti C. Management of septic skin necroses. Eur J Pediatr Surg. 2013 Oct;23(5):349-358. doi: 10.1055/s-0033-1352530. Epub 2013 Sep 5.  
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1493442/>
17. NIH/ National Institute of General Medical Sciences: Burns Fact Sheet. Last reviewed: Nov. 22, 2013.  
[http://www.nigms.nih.gov/Education/Factsheet\\_Burns.htm](http://www.nigms.nih.gov/Education/Factsheet_Burns.htm)
18. Orgill DP, Ogawa R. Current methods of burn reconstruction. Plast Reconstr Surg. 2013 May;131(5):827e-836e. doi: 10.1097/PRS.0b013e31828e2138.  
<http://www.ncbi.nlm.nih.gov/pubmed/23629122>
19. U.S. Food and Drug Administration (FDA): 510(k) Summary approval for INTEGRA™ Flowable Wound Matrix, 10/10/2007  
[http://www.accessdata.fda.gov/cdrh\\_docs/pdf7/K072113.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf7/K072113.pdf)
20. U.S. Food and Drug Administration (FDA): 510(k) Summary approval for INTEGRA™ Bilateral Matrix Wound Dressing, 8/14/2002  
[http://www.accessdata.fda.gov/cdrh\\_docs/pdf2/k021792.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf2/k021792.pdf)
21. U.S. Food and Drug Administration (FDA): 510(k) Summary approval for INTEGRA® Dermal Regeneration Template. Last updated: 09/15/2013.  
<http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm083520.htm>

### Disclaimer:

Evolent Health medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of Evolent Health and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable



## **MP.083.MH – Skin Substitutes- Human Skin Equivalents**

Policy Number: MP.083.MH  
Last Review Date: 11/08/2018  
Effective Date: 01/01/2019

Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

Evolent Health reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Evolent Health. Any sale, copying, or dissemination of said policies is prohibited.